Navigation Links
Shire Presents Positive New Data at the 60th Annual American Society of Human Genetics (ASHG) for Patients with Type 1 Gaucher Disease
Date:11/4/2010

CAMBRIDGE, Mass., Nov. 4, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today presented positive new data from a Phase III clinical trial (study 039) designed to evaluate the efficacy of VPRIV® (velaglucerase alfa for injection) compared with imiglucerase in patients with type 1 Gaucher disease at the 2010 Annual American Society of Human Genetics (ASHG) in Washington, D.C. The study met its primary endpoint and adds to the growing body of clinical evidence which supports the use of VPRIV in patients who have transitioned from imiglucerase or who are treatment-naive. 

In the 039 (head-to-head) study, adult and pediatric patients with type 1 Gaucher disease were included in a 9-month, global, randomized, double-blind, non-inferiority study comparing VPRIV with imiglucerase in treatment-naive patients aged >/= 2 years, with anemia and either thrombocytopenia or organomegaly. Patients were randomized in a 1:1 ratio to receive either VPRIV or imiglucerase at a dose of 60U/kg via continuous infusion over one hour every other week for 39 weeks (total of 20 infusions per patient). 35 patients in 9 countries were randomized and 34 received the study drug (intent-to-treat [ITT] population was 17 in both the VPRIV and imiglucerase groups). The per-protocol (PP) analysis included 15 patients in each group. Baseline clinical characteristics were generally similar between the 2 groups, although hemoglobin concentrations appeared slightly higher in the VPRIV group.

After 9 months of treatment, hemoglobin concentration improved in both groups. The estimated mean treatment difference for hemoglobin concentration from baseline between patients treated with VPRIV and imiglucerase was 0.14 and 0.16 g/dL in the ITT and PP populations, respectively, with a lower bound of the 97.5% one-sided confidence inte
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. (OTC ... U.S. provisional patent application concerning composition of matter, biological ... targeted tumor cell death.  This patent ... double stranded RNA molecules (VSRNAs) which interfere with the ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... today announced that Jeff Abbey , the ... of its Arcelis™ dendritic cell-based immunotherapy at 3:30 ... Conference in New York. In addition, Charles ... president of research and development, will participate in a panel ...
... 18 URAC, a leading independent health care quality ... (MRM) program the Bronze Award in Health Information/Decision Support ... Empowerment and Protection Awards. The awards honor programs that ... The Oklahoma Health Care Authority (OHCA) and Oklahoma Department ...
Cached Medicine Technology:Argos Therapeutics to Present Overview of its Arcelis™ Dendritic Cell-based Immunotherapy, Participate in Panel Discussion at Inaugural Cancer Immunotherapy Conference 2Health Care Coordination Program Honored With URAC National Best Practices Award 2Health Care Coordination Program Honored With URAC National Best Practices Award 3Health Care Coordination Program Honored With URAC National Best Practices Award 4
(Date:4/20/2014)... A single type of cell in the lining ... invasive bladder cancer, according to researchers at the Stanford ... mice, is the first to pinpoint the normal cell ... It,s also the first to show that most bladder ... one cell, and explains why many human bladder cancers ...
(Date:4/18/2014)... published online in The Gerontologist ... is associated with a decrease in anxiety about death ... control over their lives. In particular, listening to gospel ... death and an increase in sense of control. , ... and men, and individuals of both low- and high-socioeconomic ...
(Date:4/18/2014)... worst memories? How did it make you feel? According ... personal experience, such as how sad you were or ... especially when you can,t stop thinking about it. ... the context of the memories, rather than how you ... alleviate the negative effects of these memories, a new ...
(Date:4/18/2014)... (April 18, 2014) ― A new study in the ... patterns in health-related Google searches reveals a recurring pattern ... , Investigators from San Diego State University, ... Monday Campaigns, analyzed "healthy" Google searches (searches that included ... diet") originating in the U.S. from 2005 to 2012. ...
(Date:4/17/2014)... in benign prostate tissue was associated with high-grade, ... found even in those with low prostate-specific antigen ... Cancer Epidemiology, Biomarkers & Prevention , a ... , An analysis of prostate tissue biopsies collected ... the Prostate Cancer Prevention Trial (PCPT) found that ...
Breaking Medicine News(10 mins):Health News:Stanford scientists identify source of most cases of invasive bladder cancer 2Health News:Stanford scientists identify source of most cases of invasive bladder cancer 3Health News:Stanford scientists identify source of most cases of invasive bladder cancer 4Health News:Stanford scientists identify source of most cases of invasive bladder cancer 5Health News:Religious music brings benefit to seniors' mental health 2Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3
... Association of California Nurse Leaders Supports Research Efforts ... AMN Healthcare congratulates Tanya Osborne-McKenzie, RN, who was ... the 31st annual Association of California Nurse Leaders ... by ACNL. Osborne-McKenzie is the director of ...
... 26 Digital Power Corporation (NYSE Amex: DPW ... and for the year ended December 31, 2008.Digital Power reported ... 3l, 2008, compared to net income of $235,000 for the ... for the fourth quarter of 2008, compared to operating income ...
... SCIENTIST: A GUIDE TO RESPONSIBLE CONDUCT IN RESEARCH, THIRD ... Academy of Engineering, and Institute of Medicine, offers researchers ... on the ethical conduct of scientific research. ... to help readers consider how to respond in complex ...
... Specialized Leases from Elekta Facilitate Sharing of Financial ... health systems are facing a "perfect storm" as ... layoffs and federal cuts, and investment income dwindles. ... from other medical facilities, but from new entrants ...
... Coast Independent Review Board (IRB), testified today before the Subcommittee ... Committee in the Rayburn House Office Building. Coast IRB ... clandestine sting operation at the request of the Committee. ... Coast had committed any crime. No crime was unearthed ...
... to aid in recognizing, treating rare but real condition ... about the symptoms and outcomes of a relatively rare ... been collected by U.S. researchers into a registry of ... 70 people in the new registry -- nearly all ...
Cached Medicine News:Health News:Tanya Osborne-McKenzie Wins AMN Healthcare ACNL Scholarship 2Health News:Digital Power Reports Financial Results for the Fourth Quarter and the Year Ended December 31, 2008 2Health News:Digital Power Reports Financial Results for the Fourth Quarter and the Year Ended December 31, 2008 3Health News:Digital Power Reports Financial Results for the Fourth Quarter and the Year Ended December 31, 2008 4Health News:New Focus Placed on Alternative Financing as Hospitals Seek Competitive Advantage During Challenging Economic Conditions 2Health News:New Focus Placed on Alternative Financing as Hospitals Seek Competitive Advantage During Challenging Economic Conditions 3Health News:Coast IRB Tells Congressional Committee Sting Operation Was Illegal, Unnecessarily Harmful 2Health News:Registry Created for Broken Heart Syndrome 2
... a electronic medical records software for healthcare ... Medical Office Records does more than just ... to follow the flow of your patient ... encounters to establishing new examination records via ...
... The eCHARMS suite comprises the ... 2000 product line. Currently, there ... signature & enterprise-wide disclosure reporting. ... new HIM management tool. These ...
... Electronic Medical Office (EMO) truly built for ... unique needs of your practice. The ChartLogic™ ... record system (EMR, EHR, and EPR), and ... new level of efficiency and performance. In ...
... serving the needs of orthopaedic practices ... a better orthopaedic practice, an orthopaedic ... EMR software has been intuitively developed ... country resulting in a complete workflow ...
Medicine Products: